Goodwin advised 30 Technology on the deal. 30 Technology announced the completed the sale of its antimicrobial nitric oxide platform in certain applications to Convatec Group Plc...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised DJS Antibodies on the deal. AbbVie (NYSE: ABBV) announced the acquisition of DJS Antibodies Ltd (“DJS”), a privately-held UK-based biotechnology company dedicated to discovering...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Ducentis BioTherapeutics on the deal. Ducentis BioTherapeutics announced its acquisition by Arcutis Biotherapeutics for up to $400 million. Ducentis BioTherapeutics, a portfolio company of...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell, Mayer Brown, and Mishcon de Reya advised Gilead, while Goodwin Procter and Wilson Sonsini Goodrich & Rosati advised MiroBio on the deal....
You must be a Standard 1 Year member to access this content.
Goodwin advised ReViral on the deal. Clifford Chance advised Pfizer. ReViral announced its acquisition by Pfizer. Pfizer will acquire ReViral for a total consideration of up to...
You must be a Standard 1 Year member to access this content.
Goodwin advised SV Health, Jeito and Samsara BioCapital on the deal. SV Health, Jeito and Samsara BioCapital led a $65 million Series A Financing of EyeBio. EyeBio...
You must be a Standard 1 Year member to access this content.
Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Goodwin Procter LLP advised Centessa Pharmaceuticals on the deal. Centessa Pharmaceuticals, a clinical-stage company employing its innovative asset-centric business model...
You must be a Standard 1 Year member to access this content.
